Dominique Berton-Rigaud

Author

Institut de Cancérologie de l'Ouest

Also Known As

Amanda Feeney, D Berton-Rigaud, D. Berton-Rigaud, Dominique Berton, Dominique Berton-Rigaud

275

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Institut de Cancérologie de l'Ouest Institut Génétique Nantes Atlantique Institut Gustave Roussy Inserm Centre Léon Bérard

About

Dominique Berton-Rigaud is an author at Institut de Cancérologie de l'Ouest specializing in oncology, medicine, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	1.3K
2	Immunology	3	3	472
3	Health Sciences	2	2	37
4	Public Health	1	1	42
5	Biostatistics	1	1	42

Dominique Berton-Rigaud

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, The Lancet Oncology	2018	599
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud, Journal of Clinical Oncology	2017	504
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Caroline Rousseau, Anne Devillers, Christine Sagan, Journal of Clinical Oncology	2006	310
Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028 Andréa Varga, Sarina A. Piha‐Paul, Patrick A. Ott, Gynecologic Oncology Advanced Ovarian CancerMedicineImmunologyTumor ImmunityPathology	2018	269
Safety and dose modification for patients receiving niraparib Jonathan S. Berek, Ursula A. Matulonis, Ulla Peen, Annals of Oncology	2018	183
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. Andréa Varga, Sarina A. Piha‐Paul, Patrick A. Ott, Journal of Clinical Oncology Antitumor ActivityImmunologyGynecologyPathologyPharmacotherapy	2015	155
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier, Oncotarget	2018	134
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial Amit M. Oza, Ursula A. Matulonis, Susanne Malander, The Lancet Oncology MedicineCancer ManagementGynecologyRecurrent Ovarian CancerNiraparib Versus Placebo	2018	123
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas Delphine Loussouarn, L. Campion, Christine Sagan, British Journal of Cancer	2008	81

Page 1